Abstract:Objectives: A Patterns of Care Study (PCS) was performed in the largest regional medical center in Zhejiang Province, China. The hospital information system (HIS) was used to evaluate patient characteristics and changes in initial treatment patterns for prostate cancer and to determine recent predominant trends in treatment plans for prostate cancer (PCa) in China. Methods: Men who were newly diagnosed with localized or locally advanced PCa for 2010-2011 and 2016-2017 were identified in the HIS database. Patient characteristics and temporal trends in initial management were assessed, and differences between groups were evaluated for significance using Chi-square and Mann-Whitney U tests. Results: In total, 1792 patients met the study criteria, including 505 and 1287 patients in the 2010-2011 and 2016-2017 samples, respectively. The average age of patients diagnosed in the 2010-2011 PCS survey was 70 years, decreasing to 68 years when the 2016-2017 patients were included (P<0.001). In the 2010-2011 sample, 50.69% of the patients had an initial prostate-specific antigen (PSA) level ≥20 ng/ml. In contrast, the initial PSA level was 4-19.99 ng/ml for 66.67% of the patients in the 2016-2017 sample (P<0.001). Based on National Comprehensive Cancer Network (NCCN) criteria, the percentages of patients in low- and intermediate-risk groups increased from 33.06% to 54.78%; conversely, the percentages in high-risk, very high-risk, and regional (N1) groups decreased to a certain extent (P<0.001). According to European Association of Urology (EAU) criteria, the percentages of patients in low- and intermediate-risk groups increased from 32.07% to 53.69%, yet the percentage in the high-risk group decreased (P<0.001). The use of radical prostatectomy (RP) and radiation therapy (RT) increased from 48.32% to 76.46% and 5.35% to 16.94%, particularly in high-risk and low-risk groups, respectively, whereas the rates of hormone therapy (HT) and active surveillance and observation (AS&O) decreased from 32.28% to 4.27% and from 16.04% to 2.33%, respectively (P<0.001). A similar pattern was observed when patients were stratified by EAU risk group. Conclusions: The results of this real-world study in the largest regional medical center in Zhejiang Province, China, indicate that the predominant characteristics of PCa patients and trends in initial management are changing rapidly. We found the following: (a) a trend toward a decreased age among newly diagnosed patients; (b) a trend toward lower initial PSA levels; (c) a downward trend in risk group classification; (d) a significant increase in the likelihood of receiving RP, particularly in the high-risk group; (e) an increase in the rate of RP, mostly due to use of the Da Vinci robotic system; (f) a significant increase in the likelihood of receiving RT, especially in the low-risk group; and (g) a decrease in HT and AS&O.

Unravelling the natural history of localised prostate cancer in the post-prostate specific antigen era: implications for clinical management

Consensus on Safety Management of Novel Hormonal Therapy for Advanced Prostate Cancer

Prostate Cancer in Asia: A Collaborative Report

Trends in Treatment for Prostate Cancer in China: Preliminary Patterns of Care Study in a Single Institution

Current status of prostate biopsy in Chinese Prostate Cancer Consortium member hospitals

A prospective cohort of men with localized prostate cancer on active surveillance protocol in Hong Kong, China: what did we learn?

Management of Prostate Cancer in China: a Multicenter Report of 6 Institutions.

Recent advances and future perspectives in the therapeutics of prostate cancer

Incidental Prostate Cancer in Radical Cystoprostatectomy Specimens

Genomics in active surveillance and post-prostatectomy patients: A review of when and how to use effectively

Biomarkers for Prostate Cancer: From Diagnosis to Treatment

Pathological Features of Localized Prostate Cancer in China: a Contemporary Analysis of Radical Prostatectomy Specimens.

Implications of unconventional histological subtypes on magnetic resonance imaging and oncological outcomes in patients who have undergone radical prostatectomy

Local Treatment for Newly Diagnosed Low Prostate-Specific Antigen, High Gleason Score Prostate Cancer.

Clinical proteomics for prostate cancer: understanding prostate cancer pathology and protein biomarkers for improved disease management

From microscopes to molecules: The evolution of prostate cancer diagnostics

Unleashing novel horizons in advanced prostate cancer treatment: investigating the potential of prostate specific membrane antigen-targeted nanomedicine-based combination therapy

Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer.

Local Therapy on Clinically Lymph Node-positive Prostate Cancer: A Systematic Review and Meta-analysis

Acute toxicity of herbicide formulations and chronic toxicity of technical‐grade trifluralin to larval green frogs (Lithobates clamitans)

Prostate Cancer in Asia: Design of a Patient Registry to Inform Real-World Treatments, Outcomes, and Quality of Life.